Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Revumenib Approved for KMT2A Translocation Leukemia
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory acute leukemia with a KMT2A gene translocation in adult and pediatric patients 1 year or older. The approval makes the oral small-molecule menin…
English